ArticleFrontiers in immunology2025
The role of ATF3 in precision medicine of brain arteriovenous malformation: based on endothelial cell proliferation.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Brain arteriovenous malformation (BAVM) is a destructive high-flow vascular abnormality that can lead to various cerebral hemodynamic disorders. The incidence of BAVM has risen significantly in recent years, yet treatment options remain limited. Endothelial cells (ECs) have been proved to be one of the key factors leading to abnormal cerebrovascular structure. Therefore, it is important to explore the pathogenesis of the disease and develop new treatment strategies. With the rapid advancement of single-cell sequencing (scRNA-seq) and the integration of multi-omics data offers a novel perspective for precision medicine. Methods: We first analyzed scRNA-seq data from the GEO database. We used monocle2, CytoTRACE, and slingshot to perform pseudotime trajectory analysis on ECs. CellChat was used to analyze cell-cell communication in BAVM, and pySCENIC was used to analyze related transcription factors (TFs). Finally, transfection, CCK-8, RT-qPCR, Transwell, EdU, tube formation, and other commonly used experiments were conducted to further validate the effects of key TFs on ECs intervention. Results: scRNA-seq analysis showed that ECs in BAVM had significant specificity. C0 subpopulation was the key subpopulation, showing strong proliferation and differentiation ability. This study emphasized that the midkine(MK, MDK)signaling pathway was a significant signaling pathway. Heparin-binding growth factor midkine was a secreted protein with a molecular weight of 13 kDa. Studies had shown that it can promote endothelial cell proliferation and lead to angiogenesis. Then, the C0 subpopulation was also associated with a variety of TFs, among which ATF3 played a key role in the pathogenesis of BAVM. The possibility of ATF3 affecting the progression of BAVM was verified by cell experiments. Conclusion: This study employed scRNA-seq and multi-omics analysis to elucidate the pathogenesis of BAVM, uncovering the key role of ATF3 in ECs proliferation. Targeting ATF3 provided a new possibility for the treatment of BAVM and also made up for the blank of ATF3 in the exploration of BAVM. This study provided a theoretical basis for the personalized treatment of BAVM and demonstrated the potential of scRNA-seq and multi-omics methods in advancing precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.